Ethinylestrdiolの抗前立腺作用に関する基礎的臨床的研究,特に前立腺癌に対する制癌効果について

Abstract

We investigated the estrogenic and antiprostatic action of ethinylestradiol in rats, compared with the other synthetic estrogens, hexestrol (HEX), diethylstilbestrol (DSS), and diethylstilbestrol diphosphate (DSSP). Ethinylestradiol showed the most potent estrogenic action among them. The order of magnitude of antiprostatic action for the four synthetic estrogens was as follows: DSS 4.88>HEX 1.38> Ethinylestradiol 1.00>DSSP 0.26 (in young adult rats), DSS 2.09>Ethinylestradiol 1.00>HEX 0.47>DSSP 0.85. (in aged rats). Clinical effects of ethinylestradiol were investigated on 15 patients with prostatic cancer:10 patients who had not had previous treatment and 5 patients who had had previous treatment. Clinical effects were evaluated by the partially modified Karnofsky criteria. Three mg of ethinylestradiol was considered to have almost the same antitumor effect on prostatic cancer as 60 mg of hexestrol or 300 mg of diethylstilbestrol diphosphate.